Patents Examined by Jeffrey E. Russel
  • Compositions and methods for treating diseases by inhibiting exosome release
    Patent number: 11472846
    Abstract: A method for treating a cancer comprises administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising an anti-cancer agent having at least one secretion modifying region (SMR) peptide from HIV-1 Nef fused to at least one cell-penetrating peptide (CPP) or at least one Clusterin (Clu)-binding peptide (Clu-BP).
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: October 18, 2022
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent C. Bond, James W. Lillard, Jr., Ming Bo Huang
  • Modified glucagon molecules
    Patent number: 11472857
    Abstract: The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation. Modifications may include, for example, phosphorylation or sulfation.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: October 18, 2022
    Assignee: Purdue Research Foundation
    Inventors: Elizabeth M. Murphy Topp, Hamed Tabatabaei Ghomi, Markus Lill, Shenbaga Moorthy Balakrishnan
  • Integrated automated filtration for separation, washing and drying of peptide crystals
    Patent number: 11472835
    Abstract: The present invention describes the integration of preparative crystallization, crystal separation, crystal washing and freeze-drying processes of insulin and insulin analogues into single continuous process using pressure filtration. The process facilitates time reduction and outlines the novel design of using multiple organic solvent washes and nitrogen gas purging for the removal of imbibed water and achieve final drug substance that meets the quality specifications.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: October 18, 2022
    Inventors: Sai Srikar Kandukuri, Vibhava Shukla, Arul Marimuthu, Mukul Pathy, Partha P. Hazra
  • Polymyxin compounds
    Patent number: 11459357
    Abstract: The invention provides a polymyxin compound of formula (I) and salts, solvates and protected forms thereof, pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds and compositions in methods of treatment, such as methods for the treatment of microbial infections. The compounds of formula (I) are represented thus: wherein —R15 is a group: and —R16 is hydrogen; —R17 is hydrogen -L- is a covalent bond or methylene; and —Ar is optionally substituted aryl. The groups —X—, —R1, —R2, —R3, —R4, and —R8 are as defined herein.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: October 4, 2022
    Assignee: SPERO THERAPEUTICS, INC.
    Inventors: Pamela Brown, Michael Dawson, Mona Simonovic, Steven Boakes, Esther Duperchy, Dean Rivers, Roy Lester, Scott Coleman
  • Anti-VEGF protein compositions and methods for producing the same
    Patent number: 11459373
    Abstract: The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using anion exchange chromatography to produce aflibercept with a specific glycosylation profile. In particular, these methods produce aflibercept with a glycosylation profile with specific ranges of % total fucosylated glycans, total sialylated glycans, mannose-5, and galactosylated glycans.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: October 4, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew Tustian, Ankit Vartak, Thomas Daly, Erica Pyles, Nisha Palackal, Shunhai Wang, Ning Li
  • Anti-VEGF protein compositions and methods for producing the same
    Patent number: 11459374
    Abstract: The present disclosure pertains to methods for preparing a prefilled syringe and methods for preparing an auto injector prefilled syringe comprising aflibercept and methods for producing such aflibercept in chemically defined media.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: October 4, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew Tustian, Ankit Vartak, Thomas Daly, Erica Pyles, Nisha Palackal, Shunhai Wang, Ning Li
  • Materials and methods for treating Friedreich's Ataxia
    Patent number: 11459363
    Abstract: A Transactivator of Transcription-frataxin (TAT-FXN) fusion polypeptide useful in treating subjects diagnosed with Friedreich's Ataxia, hypertrophic cardiomyopathy, or both are disclosed, as are related methods of treatment and pharmaceutical compositions.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: October 4, 2022
    Assignee: The Trustees of Indiana University
    Inventor: Ronald Mark Payne
  • Enhancement of CD47 blockade therapy by proteasome inhibitors
    Patent number: 11446315
    Abstract: CD47? disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include SIRP?Fc as CD47 blockade drug, and one of bortezomib, ixazomib and carfilzomib as proteasome inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 20, 2022
    Assignee: PF Argentum IP Holdings LLC
    Inventors: Emma Linderoth, Natasja Nielsen Viller, Robert Adam Uger, Penka Slavcheva Slavova-Petrova
  • Administration of serine protease inhibitors to the stomach
    Patent number: 11439611
    Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: September 13, 2022
    Assignees: Leading BioSciences, Inc., The Regents of the University of California
    Inventors: Geert W. Schmid-Schonbein, Yung-Tsai (Andrew) Lee, Jeng Wei
  • Polymyxin B component or salt thereof, and preparation and application thereof
    Patent number: 11440940
    Abstract: A polymyxin B component or salts thereof, and a preparation and application thereof. The polymyxin B component includes six ?,?-diaminobutyric acids respectively at positions 1, 3-5 and 8-9, two threonine residues at positions 2 and 10, a phenylalanine residue at position 6 and a leucine residue at position 7 linked in sequence. The threonine residue at position 10 is linked to the ?,?-diaminobutyric acid at position 4 by an amido bond, and the ?,?-diaminobutyric acid at position 1 is linked to 6-methyloctyl-2-enoyl.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: September 13, 2022
    Assignee: SPH NO. 1 BIOCHEMICAL & PHARMACEUTICAL CO., LTD.
    Inventors: Hanzhi Zhang, Hao Liu, Zhenhui Huang, Ning Sun, Wenyan Luo, Jinguo Ding, Xiaofen Liu, Xingchen Bian
  • Composition for cell protection containing cyclo histidine-proline as active ingredient
    Patent number: 11433114
    Abstract: A new use of a cyclo histidine-proline (Cyclo His-Pro, CHP) is disclosed. A composition including cyclo histidine-proline (CHP) as an active ingredient has an excellent protective effect to protect kidney and liver cells from damage and/or toxicity induced by various causes. The composition is useful and effective in protecting kidney and/or liver cells/tissues and in treating a subject with kidney and/or liver diseases and/or damages.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: September 6, 2022
    Assignee: NovMetaPharma Co., Ltd.
    Inventors: Hoe-Yune Jung, Heon-Jong Lee, Jong-Su Jeon, Yon-Su Kim, Seung-Hee Yang, Yong-Chul Kim, Jong-Joo Moon, Hwan-Soo Yoo, Kyeong-Mi Choi
  • Stabilized polypeptides and uses thereof
    Patent number: 11434263
    Abstract: The present invention features polypeptides which inhibit dimerization of small multidrug resistance transporters including a stabilized ?-helix, and the use of such polypeptides in the treatment of bacterial infections.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: September 6, 2022
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Martin Karplus, Victor G Ovchinnkov
  • Anti-human papillomavirus 16 E7 T cell receptors
    Patent number: 11434272
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: September 6, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Epimerization-free N to C solid-phase peptide synthesis
    Patent number: 11427612
    Abstract: The present disclosure provides a method of solid-phase peptide synthesis from the N terminus to C terminus without detectable epimerization of the C-terminal amino acid. The method includes using derivatized amino acids comprising a diamino-aryl group.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: August 30, 2022
    Assignee: Wayne State University
    Inventors: Jennifer L. Stockdill, Christine A. Arbour
  • Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders
    Patent number: 11419833
    Abstract: A nasally administered liquid, including suspension and viscous liquid compositions, containing a therapeutically effective quantity of (Z)-2-(3,5,5-trimethyl-2-cyclohexen-1-ylidene) acetic acid, its salts or analogs, combined with suitable pharmaceutical ingredients, to treat epilepsy.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: August 23, 2022
    Inventors: Farzana Shaheen, Atta-ur Rahman, Muhammad I. Choudhary, Shabana U. Simjee, Zehra Batool
  • Peptide synthesis method
    Patent number: 11420997
    Abstract: The present invention has an object of shortening the process time and reducing use of a poor solvent for solidifying a carrier (Tag)-peptide component, by removing impurities without conducting solid-liquid separation (condensation, solid-liquid separation and drying operation) of a Tag-peptide component, in an Fmoc method using a Tag for liquid phase peptide synthesis.
    Type: Grant
    Filed: April 13, 2019
    Date of Patent: August 23, 2022
    Inventors: Hideaki Suzuki, Susumu Muto, Shuji Fujita, Daisuke Kubo
  • Compositions, methods, and systems for orally administrable affinity-based protein
    Patent number: 11407791
    Abstract: Disclosed herein are compositions comprising one or more therapeutic proteins for oral administration. The disclosed proteins, which may be directed to a variety of GI and systemic target antigens, resist denaturation and degradation in the stomach and intestines of a patient. The disclosed proteins may be delivered intact to a target region within the gut, or anywhere in body to target specific molecules, cells, tissues, or organs. In some embodiments, the disclosed proteins may include two or more proteins for targeting two or more target antigens.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: August 9, 2022
    Assignee: Auctus Biologics, Inc.
    Inventors: Adam Blanden, Aaron Wolfe
  • Methods and compositions for delivery of biotin to mitochondria
    Patent number: 11389431
    Abstract: Certain exemplary embodiments are directed to a biologically active composition of matter (and uses thereof) configured for targeted delivery of biotin to mitochondria, the composition comprising a first D-biotin conjugated to a water-soluble, cell-permeable, peptide sequence, wherein the peptide sequence is selected from a polypeptide group with an alternating aromatic-cationic motif.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: July 19, 2022
    Assignee: Social Profit Network
    Inventor: Hazel Szeto
  • Ras inhibitory peptides and uses thereof
    Patent number: 11377476
    Abstract: The present invention provides peptides comprising a sequence of X-6X-5X-4X-3X-2X-1X1PX3X4PX6X7PGX10X11AX13X14X15X16LX18X19X20X21X22X23LX25X26YLX29X30X31X32 (SEQ ID NO: 13) wherein the amino acids X?6, X?5, X?4, X?3, X?2, X?1, X1, X3, X4, X6, X7, X10, X11, X13, X14, X15, X16, X18, X19, X20, X21, X22, X25, X26, X29, X30, X31, and X32 are as defined herein. The present invention further provides pharmaceutical compositions comprising the peptides and methods of using the peptides for treating proliferative diseases such as cancer which are associated with Ras. Also provided are methods of screening a library of peptide dimers using a peptide dimer display technology.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: July 5, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, John Hanney McGee
  • Compositions and methods of treating cancer with glycomimetic peptides
    Patent number: 11376307
    Abstract: The present disclosure relates to pharmaceutical compositions comprising a peptide or multivalent polypeptide, and an anti-cancer agent. In some embodiments, the anti-cancer agent is conjugated to the peptide or multivalent polypeptide. The present disclosure also relates to a method of treating cancer or reducing cancer cell proliferation using the peptide or multivalent polypeptide. In some aspects, the peptide or multivalent polypeptide enhances the efficacy of the anti-cancer agent, the targeting of the anti-cancer agent to the cancer cells, or both.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: July 5, 2022
    Assignee: Susavion Biosciences, Inc.
    Inventors: Laura L. Eggink, J. Kenneth Hoober